Anzeige
Mehr »
Dienstag, 16.09.2025 - Börsentäglich über 12.000 News
Diese Aktie meldet Mega-Deal: Nokia & Ericsson an Bord!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4197Y | ISIN: US45674E2081 | Ticker-Symbol: 6JH0
Tradegate
15.09.25 | 16:31
1,770 Euro
-2,21 % -0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IN8BIO INC Chart 1 Jahr
5-Tage-Chart
IN8BIO INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,6701,73015.09.
1,6401,80015.09.

Aktuelle News zur IN8BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.08.IN8bio GAAP EPS of -$1.24 beats by $0.566
07.08.IN8BIO, INC. - 10-Q, Quarterly Report4
07.08.IN8BIO, INC. - 8-K, Current Report2
30.06.IN8BIO, INC. - 8-K, Current Report5
09.06.IN8bio, Inc: IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial516NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases...
► Artikel lesen
06.06.XFRA NEW INSTRUMENTS AVAILABLE ON 06.06.2025438The following instruments on XETRA do have their first trading 06.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.06.2025 Aktien 1 IT0005329815 Somec SpA 2 AU000000AIS8...
► Artikel lesen
05.06.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.06.2025721The following instruments on Boerse Frankfurt do have their last trading day on 05.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.06.2025ISIN NameFI4000561576 VALOE...
► Artikel lesen
05.06.XFRA ISIN CHANGE350Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS45674E1091 In8Bio Inc. 05.06.2025 US45674E2081 In8Bio Inc. 06.06.2025 Tausch 30:1
► Artikel lesen
IN8BIO Aktie jetzt für 0€ handeln
02.06.IN8BIO, INC. - 8-K, Current Report11
02.06.IN8bio, Inc: IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival574Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp...
► Artikel lesen
14.05.IN8bio berichtet über vielversprechende Daten zur Lupus-Behandlung9
14.05.IN8bio reports promising lupus treatment data2
07.05.IN8BIO, INC. - 10-K/A, Annual Report1
07.05.IN8BIO, INC. - 8-K, Current Report2
28.04.IN8BIO, INC. - 8-K, Current Report3
13.03.IN8bio, Inc: IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights267Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML)...
► Artikel lesen
03.03.IN8bio, Inc: IN8bio Announces Advanced Gamma-Delta T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases319Proprietary platform represents the first known approach capable of sustained gamma-delta T cell expansion, eliminating target cells with robust potencyINB-619, a next generation gamma-delta TCE targeting...
► Artikel lesen
14.02.IN8bio, Inc: IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML276NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday...
► Artikel lesen
11.02.IN8bio, Inc: IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients391100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated...
► Artikel lesen
10.12.24IN8bio, Inc: IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting241INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1